Home  »  Business   »  Prometheus Biosciences Inc. (NASDAQ: RXDX) Stock F...

Prometheus Biosciences Inc. (NASDAQ: RXDX) Stock Forecast: Downside Of -0.67% By 2023

The trading price of Prometheus Biosciences Inc. (NASDAQ:RXDX) floating lower at last check on Wednesday, May 24, closing at $198.66, -0.02% lower than its previous close.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $198.68 and $198.99. In examining the 52-week price action we see that the stock hit a 52-week high of $198.99 and a 52-week low of $22.31. Over the past month, the stock has gained 2.32% in value.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Prometheus Biosciences Inc., whose market valuation is $9.53 billion at the time of this writing, is expected to release its quarterly earnings report May 13, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.93 per share this quarter, however they have predicted annual earnings per share of -$3.9 for 2023 and -$4.31 for 2024. It means analysts are expecting annual earnings per share growth of -11.70% this year and -10.50% next year.

The average estimate suggests sales will likely down by -52.70% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $2.62 million. The company’s revenue is forecast to drop by -61.50% over what it did in 2023.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Prometheus Biosciences Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest RXDX has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned RXDX a recommendation rating is 9. Out of them, 8 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Prometheus Biosciences Inc. (RXDX) as Underweight, while 0 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that RXDX’s price is currently 2.37% off the SMA20 and 27.24% off the SMA50. The RSI metric on the 14-day chart is currently showing 82.97, and weekly volatility stands at 0.41%. When measured over the past 30 days, the indicator reaches 0.51%. Prometheus Biosciences Inc. (NASDAQ:RXDX)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 2.57. With analysts defining $160.00-$200.00 as the low and high price targets, we arrive at a consensus price target of $195.00 for the trailing 12-month period. The current price is about 19.46% off the estimated low and -0.67% off the forecast high, based on this estimate. Investors will be thrilled if RXDX’s share price rises to $200.00, which is the median consensus price. At that level, RXDX’s share price would be -0.67% below current price.

To see how Prometheus Biosciences Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: RXDX stock’s performance was -0.02% at last check in today’s session, and 575.25% in the past year, while Johnson & Johnson (JNJ) has been trading -0.11% in recent session and positioned -12.71% lower than it was a year ago. Another comparable company Eli Lilly and Company (LLY) saw its stock trading 0.76% higher in today’s session but was up 40.92% in a year. Furthermore, AbbVie Inc. (ABBV) showed a decrease of -0.11% today while its price kept declining at -3.82% over the past year. Also during today’s trading, the S&P 500 Index has plunged -0.76%, while the Dow Jones Industrial also saw a negative session, down -0.63% today.

An evaluation of the daily trading volume of Prometheus Biosciences Inc. (NASDAQ:RXDX) indicates that the 3-month average is 1.08 million. However, this figure has increased over the past 10 days to an average of 1.16 million.

Currently, records show that 47.46 million of the company’s shares remain outstanding. The insiders hold 0.20% of outstanding shares, whereas institutions hold 72.70%. The stats also highlight that short interest as of Apr 27, 2023, stood at 4.9 million shares, resulting in a short ratio of 3.04 at that time. From this, we can conclude that short interest is 10.24% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 4.75 million. However, since the stock’s price has seen 80.60% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *